Foundation Psychedelic Review
FOUNDATION LABS · PRIMARY-SOURCE INTELLIGENCE
Psychedelic medicine is entering its institutional phase. The information environment is still built for hype.
Foundation Psychedelic Review is evidence-first research for people who want to know what is clinically real, what may become commercially viable, what the market may be mispricing — and what could still break the thesis.
Get Issue Zero free →Free report. No credit card. No paid subscription starts when you opt in.
WHY THIS MOMENT MATTERS
The trade has changed.
The sector is moving out of the era when every psychedelic company could be discussed as one thematic basket. Late-stage clinical evidence is accumulating, regulators are defining the rules, capital is becoming more selective, and major pharmaceutical companies are beginning to validate specific assets rather than the category as a whole.
CLINICAL
Late-stage evidence is separating programs.
Positive Phase 3 readouts and pivotal programs now make program-by-program analysis more useful than broad sector enthusiasm.
REGULATORY
The rules are becoming explicit.
FDA guidance and the September 2026 public hearing move the conversation from category legitimacy toward evidence standards and real-world delivery.
CAPITAL
Strategic validation is arriving.
Lilly's completed acquisition of AtaiBeckley is a different signal from another small-cap financing round: sophisticated capital is underwriting selected therapeutic architectures.
THE INFORMATION PROBLEM
Good science does not automatically create a good investment.
Company releases optimize for narrative. Cross-trial comparisons can be deeply misleading. A strong clinical result can coexist with a weak balance sheet, punitive dilution, difficult reimbursement, poor clinic throughput, or an impractical treatment model.
That is why we separate the questions instead of collapsing everything into a single conviction score.
A CORE PRINCIPLE
“A best drug, best company, and best security at today's valuation can be three different answers.”
THE RESEARCH STANDARD
We do not ask an AI model what to think. We make the thesis survive evidence.
Every material conclusion is decomposed so the reader can see where the evidence ends and judgment begins.
Regulator, SEC filing, peer-reviewed paper or primary trial record
Formal company release or presentation
Credible secondary source or derived estimate
Hypothesis requiring validation
AI is used to challenge the analysis, expose disagreement, search for missing variables and stress-test interpretation. Primary sources carry the claims.
A PREVIEW FROM ISSUE ZERO
Efficacy may not be the scarcest variable.
The obvious question is: Which drug works best?
The harder commercial question is: Which treatment can actually be delivered, reimbursed, scaled and repeated economically?
A clinically spectacular therapy can still create disappointing enterprise value if the delivery architecture is too expensive or constrained. A less dramatic molecule with much better workflow economics can become the better business. Issue Zero begins modeling those variables separately.
WHAT YOU GET IN ISSUE ZERO
The Psychedelic Investment Landscape — September 2026
Compass, Definium, Helus, GH Research and Lilly/AtaiBeckley through the same analytical framework.
Where FDA posture is changing and which product-specific risks remain.
Near-term readouts, filings, hearings and pivotal-program milestones.
The financing context behind the clinical narrative.
The operational variables that may determine whether approval becomes a viable treatment business.
Not just what we think — the evidence that would force us to change our minds.
The goal is not to manufacture certainty. It is to make uncertainty legible.
WHO THIS IS FOR
Built for readers who want to do their own thinking.
- Long-horizon investors following biotech and neuropsychiatry
- Founders, operators and analysts working around the field
- Clinically literate readers who want the commercial layer
- Evidence-first readers who care about what could falsify a thesis
WHAT IT IS NOT
Not a ticker-alert service.
- No pump-and-dump language or daily trading calls
- No generic “AI consensus” presented as evidence
- No pretending clinical results are directly comparable when they are not
- No individualized investment or medical advice
START WITH THE WORK, NOT A SALES PITCH
Read Issue Zero free.
Enter your email and we will unlock the complete September 2026 research report immediately. Judge the quality of the work before deciding whether the ongoing Review deserves a place in your research stack.
IF THE WORK EARNS YOUR TRUST
Founding membership will be $10/month.
The paid Review is designed to be a compact intelligence layer rather than another feed to keep up with: one substantial monthly deep-dive, plus shorter updates when a clinical, regulatory, capital or access-economics event materially changes the landscape.
Future issues will extend the evidence base into valuation, cash-adjusted enterprise value, financing runway, dilution scenarios, catalyst probabilities, competitive positioning and care-delivery economics.
QUESTIONS
Before you subscribe to anything.
No. Foundation Psychedelic Review is independent educational research and analysis, not individualized investment, legal, tax or medical advice.
Regulators, SEC filings, trial registries and primary trial records, peer-reviewed literature, formal company disclosures and carefully labeled secondary or derived evidence.
The planned paid cadence is one substantial monthly research issue plus shorter updates when material events justify them.
Nothing is charged automatically. You remain on the research email list unless you unsubscribe. When paid membership opens, you can choose whether to join.
No. Issue Zero is free and the form does not start a paid subscription.